GENE ONLINE|News &
Opinion
Blog

2020-12-18| Asia-PacificR&D

NASH Drug Candidate, ASC42 Receives Fast Track Designation

by GeneOnline
Share To

A Non-Alcoholic Steatohepatitis (NASH) drug candidate ASC42, a Farnesoid X Receptor (FXR) Agonist from Gannex, received Fast Track designation from the U.S. Food and Drug Administration (FDA) on 14th December 2020.

The U.S. FDA’s Fast track is a process designed to facilitate new drug development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. Its purpose is to get important new drugs to the patient earlier. This Fast Track designation represents the FDA’s recognition of ASC42’s potential in addressing these unmet medical needs for NASH patients.

 

Regulatory History of ASC42

Gannex is a wholly-owned company of Ascletis Pharma Inc. and fully dedicated to the R&D and commercialization of new drugs in the field of NASH. Gannex received the investigational new drug application (IND) approval for ASC42 from the U.S. FDA in October this year. ASC42 is an in-house developed, novel non-steroidal, selective, potent FXR agonist with best-in-class potential. In two NASH animal models, ASC42 demonstrated significant improvements in liver steatosis, inflammation, and fibrosis. The oral tablet formulation of ASC42 has been developed with in-house proprietary technology and is stable at room temperature.

 

NASH

NASH is a progressive liver disease caused by excessive accumulation of fat in the liver. It can cause chronic inflammation in the liver, trigger progressive liver fibrosis, cirrhosis, and ultimately lead to liver failure, cancer, and patient death. The liver-related mortality in patients with advanced fibrosis is significantly increased. However, there are no FDA approved medicines for NASH indication yet.

At present, NASH is predicted to be one of the largest drug markets in the field of drug treatment for liver diseases after hepatitis C. It is estimated that the global NASH therapeutic drug market will reach US$ 40 billion in 2025. In addition to Gannex’s ASC42, Potential drugs with rapid progress in clinical research include, e.g., GENFIT’s PPAR receptor agonist Elafibranor, Intercept’s farnesol receptor (FXR) agonist obeticholic acid (OCA), Allergan’s CCR2/CCR5 chemokine receptor blocker Cenicriviroc (CVC), Gilead’s anti-apoptotic signal-regulating kinase 1 (ASK1) inhibitor Selonsertib, and Inventiva’s pan-PPAR agonist Lanifibranor.

Related Article: Gilead and Novo Nordisk Present Proof-of-Concept Data for the First Possible NASH Treatment

Partner Article, By James Hou, Ph.D.

 

 

References
  1. https://www.ascletis.com/news_detail/172/id/443.html

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Mesoblast’s Resubmission Brings First-of-its-Kind Therapy One Step Closer to Approval
2023-03-09
Pfizer and GSK Neck and Neck for First FDA-Approved RSV Vaccine
2023-03-03
South Korea Puts Everest Medicines’ Nefecon On Fast Track
2023-02-10
LATEST
GSK Bets $593 Million To License Scynexis’ Oral Antifungal
2023-03-31
3D Printed Brain Model Could Aid in Neurosurgery
2023-03-31
Latest Study on Neuronal Gene Expression May Shed Light on the Memory Formation Process
2023-03-30
Emergent BioSolutions’ Over-The-Counter Naloxone Nasal Spray Receives FDA Greenlight
2023-03-30
Current Trends of iPSC Manufacturing and Clinical Applications – An Interview with Professor Xianmin Zeng
2023-03-29
U.S.-German Joint Discovery May Spark Breakthrough in Diabetes Research
2023-03-29
Merck Regains Worldwide Rights to BAVENCIO After Parting Ways with Pfizer
2023-03-29
Scroll to Top